PETER MACCALLUM CANCER INSTITUTE Patent applications |
Patent application number | Title | Published |
20150291698 | Methods and Products for Preventing and/or Treating Metastatic Cancer - The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR. | 10-15-2015 |
20140128450 | Cancer Therapy - The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein. | 05-08-2014 |
20130302377 | STIMULATING IMMUNE RESPONSE - Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent. | 11-14-2013 |
20130109678 | RADIOPROTECTOR COMPOUNDS AND METHODS | 05-02-2013 |
20130065897 | COMPOUNDS, PREPARATION AND USES THEREOF - The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity. | 03-14-2013 |
20110190244 | METHOD OF TREATMENT OF EGFR INHIBITOR TOXICITY - The invention provides a method of treating and/or preventing a toxicity associated with epidermal growth factor receptor (EGFR) inhibitor therapy in a subject, the method comprising administering to the subject an effective amount of a steroid sulfatase (STS) inhibitor. The toxicity may be ocular toxicity; or dermatologic toxicity, such as papulopustular rash. The EGFR inhibitor may be selected from the group consisting of: a small molecule; an antibody or derivative or fragment thereof; another agent that targets the extracellular or intracellular domain of the EGFR, such as a tyrosine kinase inhibitor selected from the group consisting of: erlotinib; gefitinib; lapatinib; and any combination thereof. The EGFR inhibitor may also be antibody selected from the group consisting of: cetuximab; panitumumab; and any combination thereof. | 08-04-2011 |
20110171642 | Analysing Methylation Specific PCR by Amplicon Melting - The present invention provides a method of evaluating DNA methylation in a sample. The method comprises (i) reacting the DNA with an agent that differentially modifies methylated cytosine and non-methylated cytosine to produce modified DNA, (ii) amplifying the modified DNA by methylation specific PCR to produce amplified DNA, and (iii) subjecting the amplified DNA to melting analysis. In the method the methylation specific primers are selected such that the sequence between the primers includes a region of known sequence variation and/or at least one cytosine nucleotide. | 07-14-2011 |
20110081331 | CANCER THERAPY - The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein. | 04-07-2011 |
20100261180 | RECOMBINANT PERFORIN, EXPRESSION AND USES THEREOF - The present invention relates to retroviral vectors capable of driving the expression of perforin in a cell and a method of expressing recombinant perforin in a cell. The present invention also relates to recombinant perforin polypeptides and nucleic acid molecules derived therefrom and uses thereof. Also encompassed are screening assays employing such recombinant perforin molecules, compounds identified by the screening assays and uses thereof. | 10-14-2010 |